233 related articles for article (PubMed ID: 8996351)
21. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
[TBL] [Abstract][Full Text] [Related]
22. [Correlation between bone gammagraphy and biochemical parameters in bone turnover in patients with prostate cancer].
Alcover J; Fernández-Conde M; Filella X; de Osaba MJ; Carretero P
Actas Urol Esp; 1994 Jun; 18(6):623-7. PubMed ID: 7524277
[TBL] [Abstract][Full Text] [Related]
23. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer.
Gleave ME; Coupland D; Drachenberg D; Cohen L; Kwong S; Goldenberg SL; Sullivan LD
Urology; 1996 May; 47(5):708-12. PubMed ID: 8650870
[TBL] [Abstract][Full Text] [Related]
24. The clinical utility of prostate-specific antigen and bone scintigraphy in prostate cancer follow-up.
Freitas JE; Gilvydas R; Ferry JD; Gonzalez JA
J Nucl Med; 1991 Jul; 32(7):1387-90. PubMed ID: 1712383
[TBL] [Abstract][Full Text] [Related]
25. [Bone scan findings in a North African ethnic group and relation to PSA level and Gleason score of the biopsy].
Janane A; Jawad C; Hajji F; Ould T; Ghadouane M; Ameur A; Abbar M; Albouzidi A
Actas Urol Esp; 2011 Oct; 35(9):534-9. PubMed ID: 21664008
[TBL] [Abstract][Full Text] [Related]
26. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate?
Wolff JM; Zimny M; Borchers H; Wildberger J; Buell U; Jakse G
Eur Urol; 1998; 33(4):376-81. PubMed ID: 9612680
[TBL] [Abstract][Full Text] [Related]
27. [Correlation of prostatic specific antigen, tumor grade, and local stage with bone scintigraphy in the staging of patients with prostatic cancer].
Herranz Amo F; Díez Cordero JM; Verdú Tartajo F; Lledó García E; Subirá Castillón C; González Chamorro F; Rodríguez Fernández E
Arch Esp Urol; 1997 Apr; 50(3):253-8. PubMed ID: 9144973
[TBL] [Abstract][Full Text] [Related]
28. Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy.
Terris MK; Klonecke AS; McDougall IR; Stamey TA
J Nucl Med; 1991 Sep; 32(9):1713-7. PubMed ID: 1715394
[TBL] [Abstract][Full Text] [Related]
29. Procollagen type I carboxyterminal extension peptide in serum: a reliable marker of bone metastatic disease in newly diagnosed prostate cancer?
Perachino M; Di Ciolo L; Barbetti V; Puppo P
Eur Urol; 1996; 29(3):366-9. PubMed ID: 8740025
[TBL] [Abstract][Full Text] [Related]
30. [Impact of specific prostatic antigen on the rationalization of the use of bone gammagraphies in the follow-up of hormone-treated non- metastatic prostatic cancer].
Morote Robles J; Reig Ruiz C; Vila Barja J; López Pacios MA; de Torres Mateos JA; Soler Roselló A
Actas Urol Esp; 1993 May; 17(5):292-4. PubMed ID: 7688176
[TBL] [Abstract][Full Text] [Related]
31. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer.
Miller PD; Eardley I; Kirby RS
Br J Urol; 1992 Sep; 70(3):295-8. PubMed ID: 1384920
[TBL] [Abstract][Full Text] [Related]
32. Association between bone scintigraphy and serum levels of procollagen (I) and PSA in the detection of bone disease in prostate cancer patients.
Zissimopoulos A; Bantis A; Stellos K; Petrakis G; Matthaios D
J BUON; 2008; 13(1):69-74. PubMed ID: 18404790
[TBL] [Abstract][Full Text] [Related]
33. Levels of alpha 2 macroglobulin can predict bone metastases in prostate cancer.
Kanoh Y; Ohtani N; Mashiko T; Ohtani S; Nishikawa T; Egawa S; Baba S; Ohtani H
Anticancer Res; 2001; 21(1B):551-6. PubMed ID: 11299802
[TBL] [Abstract][Full Text] [Related]
34. Bone scan in initial staging of prostate cancer.
Boughattas S; Letaief B; Hassine H; Chatti K; Essabah H
Tunis Med; 2003 Jun; 81(6):400-6. PubMed ID: 14534946
[TBL] [Abstract][Full Text] [Related]
35. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
Morote J; Lorente JA; Encabo G
Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
[TBL] [Abstract][Full Text] [Related]
36. Chest-Wall Metastasis of Prostate Cancer.
Matei V; Bhushan S
J Gen Intern Med; 2015 Dec; 30(12):1888. PubMed ID: 25759188
[No Abstract] [Full Text] [Related]
37. Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment.
Yahara J; Noguchi M; Noda S
BJU Int; 2003 Sep; 92(4):379-83; discussion 383-4. PubMed ID: 12930424
[TBL] [Abstract][Full Text] [Related]
38. High dose hook effect in serum total and free prostate specific antigen in a patient with metastatic prostate cancer.
Furuya Y; Cho S; Ohta S; Sato N; Kotake T; Masai M
J Urol; 2001 Jul; 166(1):213. PubMed ID: 11435864
[No Abstract] [Full Text] [Related]
39. Metastatic prostate cancer with a normal prostate-specific antigen level.
Ruiz-Martín I; Rodríguez-Sánchez CA; Ocaña-Fernández A; del Valle-Zapico J; Soto de Prado-Otero D; Cruz-Hernández JJ
Clin Transl Oncol; 2005 Oct; 7(9):412-3. PubMed ID: 16238977
[TBL] [Abstract][Full Text] [Related]
40. [Usefulness of bone-specific alkaline phosphatase for bone metastases detection in prostate cancer].
Rasch-Isla Muñoz A; Cataño Cataño JG
Arch Esp Urol; 2004 Sep; 57(7):693-8. PubMed ID: 15536950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
